TRIGR Therapeutics, ABL Bio collaborate on next generation therapeutic antibodies

This article was originally published here

TRIGR Therapeutics and ABL Bio have entered into a binding agreement for TRIGR to license the global commercial rights to ABL Bio’s pipeline of novel therapeutic antibodies to treat cancer.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply